Skip to main content
. 2013 Jun 28;8(6):e67904. doi: 10.1371/journal.pone.0067904

Figure 2. OVA-specific CD8+ T cell responses in tumor challenged and non-tumor-challenged mice.

Figure 2

C57BL/6 mice were challenged with E.G7 and then, 7 days post tumor challenge, were treated as indicated. A and B. On day 9 post treatment the levels of OVA-specific CD8+ T cells, as a percentage of total CD8+CD3+ cells, were determined using a fluorescently-tagged OVA tetramer (see materials and methods for further details) in samples from the spleen (A) and the lymph node (B). The percentages were normalized against the mean values obtained for the naïve groups. Mean percentage values for the naïve group prior to normalization were 0.26% (range 0.16–0.39%) for the lymph node and 0.68% (range 0.54–0.89%) for the spleen. Data represents pooled data from four separate experiments, where the number of mice/treatment group in each experiment was n = 1, n = 2, n = 2 and n = 4 and therefore a total of n = 9 mice from each pooled treatment group were analyzed. Statistical significance was determined using an ANOVA one way analysis of variance (with Tukey post-test) (**P<0.01, ***P<0.001). C . Non-tumor-challenged mice (n = 4 per group) were vaccinated with indicated treatments and then the levels of OVA-specific CD8+ T cells in the peripheral blood were measured on days 7, 15 and 21. These results were shown to be reproducible. Error bars represent standard error of the mean.